Published Date: 2019-06-20 | Pages: Ongoing | Tables: Ongoing | Report ID: 7239
Industry: Life Science
Follicular lymphoma appears in approximately 10-20% of all lymphomas diagnosed in the West. It is the second-most frequently occurring non-Hodgkin lymphoma and has a small predominance in women. The median age at the time of diagnosis of follicular lymphoma is 60 years. Follicular lymphoma therapeutic approaches have been substantially changed in the recent time due to the availability of rituximab. This has resulted in R-chemo becoming the standard induction first-line treatment for follicular lymphoma. The median overall survival is considered to be partly improved because of the advent of rituximab. Follicular lymphoma treatments range from a ‘watch and wait’ policy to hematopoietic stem cell transplantation.
According to a new study by researchers from the University of Texas MD Anderson Cancer Center, compared to the approach of observation, minimally toxic first-line therapies could be more beneficial for patients with early-stage extranodal follicular lymphoma. The study was published early in 2019 in the peer-reviewed journal Clinical Lymphoma, Myeloma & Leukemia. The introduction of new therapies is anticipated to create a number of growth opportunities in the global follicular lymphoma treatment market.
Factors such as high number of follicular lymphoma cases and family history of the disease are foreseen to fuel the demand in the global follicular lymphoma treatment market. In addition, the growing prevalence of blood disorders across the world is prophesied to highlight the global market in the coming years. Furthermore, technological development in the diagnosis of follicular lymphoma is predicted to set the tone for substantial growth of the global market. However, the danger of adverse side effects associated with certain follicular lymphoma treatments, expensive cost of treatment, and tight regulatory conditions are expected to restrict the global market growth.
● Targeted Therapy
By End User
● Specialty Centers
● Cancer Research Institutes
Among treatments, targeted therapy is expected to account for a significant share of the global follicular lymphoma treatment market. The use of monoclonal antibodies and other targeted therapies is considered to be a better approach to the treatment of follicular lymphoma, compared to radiation and chemotherapy. Targeted therapies are used to directly target tumor cells and strengthen immune cells in the patient’s body. If end users of follicular lymphoma treatment are taken into account, hospitals are anticipated to collect a remarkable share of the global market.
The increasing incidence of follicular lymphoma is foretold to push the growth of North America in the global follicular lymphoma treatment market. The region could also witness a rise in its market growth due to increasing investments in research and development for the introduction of new drugs in the industry. Asia Pacific, on the other hand, is projected to show considerable growth in the global market because of the rising number of government initiatives to prevent different types of cancer.
The report includes deep analysis of leading companies operating in the global follicular lymphoma treatment market such as Roche, Bayer AG, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Johnson and Johnson, Pharmacyclics, CTI Biopharma, Seattle Genetics, Celgene, Merck & Co., AbbVie Inc., Amgen, and Novartis.
For an encyclopedic assessment of the global follicular lymphoma treatment market, QY Research has provided verifiable projections about the market size, historical data, and deep qualitative and quantitative insights. The researchers have used near-accurate assumptions and proven research methodologies to derive different projections related to the global market such as CAGR, value, and volume as well as the market growth of regional and segmental markets. The research study serves as a repository of intelligent analyses of the global market, including manufacturing cost analysis, Porter’s Five Forces analysis, SWOT analysis, company analysis, and demand and supply analysis.
Reasons to Buy this Report
NOTE - The analysis, thoughts, views, facts, and opinions expressed in this report are of the respective research analysts. QYR Consulting does not necessarily endorse it or it is also not essentially formal views of QYR Consulting.
Life sciences is a wide branch of study that is gradually becoming an integral industry to the global economics. QYR Consulting looks at the steady transformation of the life sciences industry and its impact on the subindustries such as medical care, pharmaceutical, and medical devices. Our team of esteemed analysts have put together reports to analyze the monumental changes life sciences is expected to bring in the overall healthcare industry. These reports identify the exact turning points for the industry and open up a platform for discussing its growth.
QYR Consulting brings to you a structured analysis of the technological advancements so far, vision of the players in the industry, and the strategies they are likely to use to make their mark. The reports dissect various components of the life sciences industry to scrutinize the influential factors. To help the readers make profitable business decisions, analysts have highlighted the lucrative investment areas and upcoming business opportunities.
Request for data as per your requirement
Get specifications suitable to your business
Receive an in-depth and unique understanding of the subject matter
Acquire insight into specific area of the industry